LAWRENCE BLATT - 15 Mar 2023 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Executive Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Lawrence M. Blatt
Issuer symbol
ALGS
Transactions as of
15 Mar 2023
Transactions value $
$0
Form type
4
Filing time
17 Mar 2023, 16:09:57 UTC
Previous filing
11 Jul 2022
Next filing
12 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +242,500 $0 242,500 15 Mar 2023 Common Stock 242,500 $1.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.